Anja Strangfeld - Concepedia

Author

Anja Strangfeld

Also Known As

A Strangfeld, A. Strangfeld, Almut Meyerbahl, Anja Strangfeld, Anja Strangfeld (chair), Christina Ye, Gossec, Laure, Katherine D. Wysham, M. Weinblatt, Rebecca Hasseli

279

Publications

13.5K

Citations

H-Index

Concepts

All Affiliations

German Rheumatism Research Centre Charité - Universitätsmedizin Berlin University of Manchester Versus Arthritis Manchester University NHS Foundation Trust

About

Anja Strangfeld is an author at German Rheumatism Research Centre specializing in public health, medicine, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	97
2	Public Health	3	3	97
3	Epidemiology	2	2	67
4	Endocrinology	1	1	30
5	Global Health	1	1	48

Anja Strangfeld

Publications

12.2K

Citations

H-Index

Page 1

	Year	Citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, Annals of the Rheumatic Diseases	2020	2.6K
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update Josef S Smolen, Robert Landewé, Sytske Anne Bergstra, Annals of the Rheumatic Diseases	2022	1.6K
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Milena Gianfrancesco, Kimme L Hyrich, Sarah Al-Adely, Annals of the Rheumatic Diseases	2020	1.2K
Infections in patients with rheumatoid arthritis treated with biologic agents Joachim Listing, Anja Strangfeld, S. Kary, Arthritis & Rheumatism	2005	684
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Anja Strangfeld, Martin Schäfer, Milena Gianfrancesco, Annals of the Rheumatic Diseases	2021	682
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents Anja Strangfeld JAMA	2009	538
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Anja Strangfeld, Maria Eveslage, Matthias Schneider, Annals of the Rheumatic Diseases	2011	358
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab Joachim Listing, Jörn Kekow, Bernhard Manger, Annals of the Rheumatic Diseases	2013	281
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT Anja Strangfeld, Franka Hierse, Rolf Rau, Arthritis Research & Therapy	2010	257
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, Annals of the Rheumatic Diseases	2021	236

Page 1